ViaLase Laser is intended to deliver a noninvasive glaucoma treatment. Credit: Inside Creative House / Shutterstock.com.

ViaLase has concluded the enrolment of adult patients in the VIA-002 pivotal trial for the treatment of primary open-angle glaucoma (POAG) using the ViaLase Laser.

The ViaLase Laser integrates femtosecond laser technology, precision and micron-level image guidance accuracy for delivering a noninvasive glaucoma treatment known as femtosecond laser image-guided high-precision trabeculotomy (FLigHT).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The randomised, controlled, prospective and multi-centre study is designed to compare the use of the ViaLase Laser against selective laser trabeculoplasty (SLT) in adult patients with POAG.

In the trial, 152 patients have been randomised to either the SLT or ViaLase Laser.

A reduction in mean unmedicated intraocular pressure (IOP) from baseline to six months and 12 months is the primary effectiveness endpoint of the trial.

The percentage of eyes with a >20% reduction in unmedicated IOP at the same period with no secondary surgical intervention for glaucoma treatment is one of the secondary effectiveness endpoints.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A reduction in the mean number of hypotensive medications from screening to six months and 12 months is the other secondary effectiveness endpoint.

ViaLase founder and CEO Tibor Juhasz said: “We are optimistic that our pivotal trial will demonstrate the safety and efficacy of the first-ever FLigHT treatment performed by the ViaLase Laser.

“Ultimately, it is our greatest wish to be able to provide an effective, noninvasive treatment to the millions of people living with glaucoma, one of the leading causes of irreversible blindness worldwide.”